{
    "xml": "<topic id=\"PHP2240\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/perphenazine\" basename=\"perphenazine\" title=\"PERPHENAZINE\">\n<title>PERPHENAZINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_381\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/phenothiazines/perphenazine\">Perphenazine</xref>\n</p>\n<data name=\"vtmid\">41147003</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_182743901\" title=\"Antipsychotics (first-generation)\">Antipsychotics (first-generation)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" title=\"ANTIPSYCHOTIC DRUGS\" namespace=\"/drug-classes/antipsychotic-drugs\">ANTIPSYCHOTIC DRUGS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n</body>\n<topic id=\"PHP42069\" outputclass=\"indicationsAndDose\" rev=\"1.23\" parent=\"/drugs/perphenazine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Schizophrenia and other psychoses</p>\n<p outputclass=\"therapeuticIndication\">Mania</p>\n<p outputclass=\"therapeuticIndication\">Short-term adjunctive management of anxiety</p>\n<p outputclass=\"therapeuticIndication\">Severe psychomotor agitation, excitement, and violent or dangerously impulsive behaviour</p>\n<p outputclass=\"therapeuticIndication\">Severe nausea and vomiting unresponsive to other anti-emetics</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 4&#8239;mg 3 times a day, adjusted according to response; maximum 24&#8239;mg per day.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>Initially 1&#8211;2&#8239;mg 3 times a day; maximum 12&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42118\" outputclass=\"contraindications\" rev=\"1.13\" parent=\"/drugs/perphenazine\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Agitation in the elderly</ph>; <ph outputclass=\"contraindication\">CNS depression</ph>; <ph outputclass=\"contraindication\">comatose states</ph>; <ph outputclass=\"contraindication\">phaeochromocytoma</ph>; <ph outputclass=\"contraindication\">restlessness in the elderly</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42143\" outputclass=\"cautions\" rev=\"1.20\" parent=\"/drugs/perphenazine\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<sectiondiv outputclass=\"additionalCautions\">\n<sectiondiv outputclass=\"cautionsOrContraindicationsWithRoutes\">\n<p outputclass=\"title\">With oral use</p>\n<p>\n<ph outputclass=\"caution\">hypothyroidism</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42000\" outputclass=\"sideEffects\" rev=\"1.22\" parent=\"/drugs/perphenazine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Systemic lupus erythematosus</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Dystonic reactions</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>Less sedating.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Acute dystonic reactions</p>\n<p>Phenothiazines can all induce acute dystonic reactions such as facial and skeletal muscle spasms and oculogyric crises; children (especially girls, young women, and those under 10&#8239;kg) are particularly susceptible.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42039\" outputclass=\"pregnancy\" parent=\"/drugs/perphenazine\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p>\n<p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42153\" outputclass=\"breastFeeding\" parent=\"/drugs/perphenazine\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.</p>\n<p>\n<i>Animal</i> studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.</p>\n<p>Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p>\n<p>Phenothiazine derivatives are sometimes used in breast-feeding women for short-term treatment of nausea and vomiting.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42085\" outputclass=\"hepaticImpairment\" parent=\"/drugs/perphenazine\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Can precipitate coma; phenothiazines are hepatotoxic.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42015\" outputclass=\"renalImpairment\" parent=\"/drugs/perphenazine\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Start with small doses in severe renal impairment because of increased cerebral sensitivity.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP2240-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/perphenazine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: tablet, oral suspension</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85569\" namespace=\"/drugs/amitriptyline-with-perphenazine\" title=\"AMITRIPTYLINE WITH PERPHENAZINE\" count=\"1\" rel=\"backlink\">AMITRIPTYLINE WITH PERPHENAZINE</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78155\" namespace=\"/treatment-summaries/psychoses-and-related-disorders\" title=\"Psychoses and related disorders\" count=\"2\" rel=\"backlink\">Psychoses and related disorders</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78221\" namespace=\"/treatment-summaries/nausea-and-labyrinth-disorders\" title=\"Nausea and labyrinth disorders\" count=\"1\" rel=\"backlink\">Nausea and labyrinth disorders</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_381\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/phenothiazines/perphenazine\" title=\"Perphenazine\" count=\"1\" rel=\"link\">Perphenazine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" namespace=\"/drug-classes/antipsychotic-drugs\" title=\"ANTIPSYCHOTIC DRUGS\" count=\"1\" rel=\"link\">ANTIPSYCHOTIC DRUGS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n</links>\n</topic>",
    "id": "PHP2240",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/perphenazine",
    "basename": "perphenazine",
    "title": "PERPHENAZINE",
    "interactants": [
        {
            "id": "bnf_int_381",
            "label": "Perphenazine"
        }
    ],
    "vtmid": "41147003",
    "drugClassification": [
        "Antipsychotics (first-generation)"
    ],
    "inheritsFromClass": [
        "ANTIPSYCHOTIC DRUGS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Schizophrenia and other psychoses",
                        "html": "Schizophrenia and other psychoses"
                    },
                    {
                        "textContent": "Mania",
                        "html": "Mania"
                    },
                    {
                        "textContent": "Short-term adjunctive management of anxiety",
                        "html": "Short-term adjunctive management of anxiety"
                    },
                    {
                        "textContent": "Severe psychomotor agitation, excitement, and violent or dangerously impulsive behaviour",
                        "html": "Severe psychomotor agitation, excitement, and violent or dangerously impulsive behaviour"
                    },
                    {
                        "textContent": "Severe nausea and vomiting unresponsive to other anti-emetics",
                        "html": "Severe nausea and vomiting unresponsive to other anti-emetics"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 4 mg 3 times a day, adjusted according to response; maximum 24 mg per day.",
                        "html": "<p>Initially 4&#8239;mg 3 times a day, adjusted according to response; maximum 24&#8239;mg per day.</p>"
                    },
                    {
                        "textContent": "Initially 1&#8211;2 mg 3 times a day; maximum 12 mg per day.",
                        "html": "<p>Initially 1&#8211;2&#8239;mg 3 times a day; maximum 12&#8239;mg per day.</p>",
                        "ageGroup": "elderly"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Agitation in the elderly",
                "html": "Agitation in the elderly"
            },
            {
                "type": "contraindications",
                "textContent": "CNS depression",
                "html": "CNS depression"
            },
            {
                "type": "contraindications",
                "textContent": "comatose states",
                "html": "comatose states"
            },
            {
                "type": "contraindications",
                "textContent": "phaeochromocytoma",
                "html": "phaeochromocytoma"
            },
            {
                "type": "contraindications",
                "textContent": "restlessness in the elderly",
                "html": "restlessness in the elderly"
            }
        ]
    },
    "cautions": {
        "cautionsOrContraindicationsWithRoutes": [
            {
                "type": "cautionsOrContraindicationsWithRoutes",
                "textContent": "hypothyroidism",
                "html": "hypothyroidism",
                "specificity": {
                    "textContent": "With oral use",
                    "html": "With oral use",
                    "routes": [
                        "oral"
                    ]
                }
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Systemic lupus erythematosus",
                        "html": "Systemic lupus erythematosus",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Dystonic reactions",
                        "html": "Dystonic reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "textContent": "Less sedating.",
                "html": "<p>Less sedating.</p>"
            },
            {
                "type": "advice",
                "title": "Acute dystonic reactions",
                "textContent": "Phenothiazines can all induce acute dystonic reactions such as facial and skeletal muscle spasms and oculogyric crises; children (especially girls, young women, and those under 10 kg) are particularly susceptible.",
                "html": "<p>Phenothiazines can all induce acute dystonic reactions such as facial and skeletal muscle spasms and oculogyric crises; children (especially girls, young women, and those under 10&#8239;kg) are particularly susceptible.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.\n\nFollowing maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.",
                "html": "<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p><p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.\n\nAnimal studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.\n\nChronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.\n\nPhenothiazine derivatives are sometimes used in breast-feeding women for short-term treatment of nausea and vomiting.",
                "html": "<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.</p><p>\n<i>Animal</i> studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.</p><p>Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p><p>Phenothiazine derivatives are sometimes used in breast-feeding women for short-term treatment of nausea and vomiting.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Can precipitate coma; phenothiazines are hepatotoxic.",
                "html": "<p>Can precipitate coma; phenothiazines are hepatotoxic.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Start with small doses in severe renal impairment because of increased cerebral sensitivity.",
                "html": "<p>Start with small doses in severe renal impairment because of increased cerebral sensitivity.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "tablet",
                "oral suspension"
            ]
        }
    },
    "backlinks": {
        "drug": [
            {
                "id": "PHP85569",
                "label": "AMITRIPTYLINE WITH PERPHENAZINE",
                "type": "drug"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78155",
                "label": "Psychoses and related disorders",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78221",
                "label": "Nausea and labyrinth disorders",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_381",
                "label": "Perphenazine",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34569",
                "label": "ANTIPSYCHOTIC DRUGS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ]
    }
}